Vaderis Therapeutics

News

Our round-up of venture capital financings in biotech this week features Vaderis, Aureka, Epicrispr, Infinimmune, and Boulevard Bio.

News

A trial of Vaderis' AKT inhibitor engasertib finds it could be the first effective treatment for rare disease hereditary haemorrhagic telangiectasia.

News

Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.